The Evolution of Quality by Design (QbD) for Biologics

References

1. 1.↵
   Submission of quality information for biotechnology products in the Office of Biotechnology Products; notice of pilot program. Federal Register 2008, 73(128).
2. 2.↵
   Notice of extension of deadlines to request participation in pilot program and to submit applications; and notice of increase in the number of original applications in pilot program. Federal Register 2009, 74(179).
3. 3.↵
   A-Mab: A Case Study in Bioprocess Development. CMC Biotech Working group: version 2.1, October 2009.
4. 4.↵
   A-VAX: Applying Quality by Design to Vaccines. CMC Vaccines Working Group: version 1.0 May 2012.
5. 5.↵
   1. Krummen L.

   Quality by Design Implementation for Biologics: Lessons Learned from the FDA Pilot Program. International Conference on Accelerating Biopharmaceutical Development and Quality by Design in Biologics, AIChE proceedings, February 27, 2013.
6. 6.↵
   1. Martin-Moe S.,
   2. Lim F. J.,
   3. Wong R. L.,
   4. Sreedhara A.,
   5. Sundaram J.,
   6. Sane S. U.

   A new roadmap for biopharmaceutical drug product development: integrating development, validation, and quality by design. J. Pharm. Sci. 2011, 100(8), 3031–3043.

   OpenUrlPubMed
7. 7.↵
   FDA Guidance for Industry: Process Validation: General Principles and Practices; U.S. FDA: Rockville, MD, January 2011.
8. 8.↵
   FDA Revision 2. Q8 (R2) Pharmaceutical Development; U.S. FDA: Rockville, MD, January 2011.
9. 9.↵
   FDA/EMEA Questions and Answers on Design Space Verification. EMEA/603905/2013, 2013.
10. 10.↵
    EMEA. ICH topic M4Q, Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality; Overall Summary of Module 2 and Module 3: Quality, CPMP/ICH/2887/99, 2003.